Skip to Content


Carolyn Y. Johnson, quoting Rachel Sachs (Academic Fellow Alumna)
The Washington Post
May 10, 2018

Read the Full Article

From the article:

President Trump will deliver Friday afternoon a twice-delayed, much-anticipated speech about his plan to lower drug prices — after a year when harsh rhetoric against drugmakers was accompanied by little action.

No one with a stake in drug prices — whether pharmaceutical companies, pharmacy benefit managers that negotiate on drug prices or health insurers — feels completely comfortable, given Trump's tendency to go off-script — including that time he accused drug companies of “getting away with murder.” But the administration has spent the past few weeks dropping clues about the policy directions it favors — including a slew of technical proposals that do little to threaten the pharmaceutical industry that would seem to be at greatest risk from any plan to lower drug prices.

“Let’s be really clear, the administration has put out a number of different sets of proposals under the heading of: Things that would address drug pricing. None of them would affect the underlying drivers of the problem,” said Rachel Sachs, an associate professor of law at Washington University School of Law. “Most of them would do very little for the 100 to 200 million Americans who are on private insurance.”

Read the full article here!

Read the Full Article

Tags

pharmaceuticals   rachel sachs